385 related articles for article (PubMed ID: 12584694)
1. Bisphosphonates for the prevention of bone metastases.
Coleman RE
Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
[TBL] [Abstract][Full Text] [Related]
2. Toward new horizons: the future of bisphosphonate therapy.
Lipton A
Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
[TBL] [Abstract][Full Text] [Related]
4. Emerging strategies in bone health management for the adjuvant patient.
Coleman RE
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
[TBL] [Abstract][Full Text] [Related]
5. Future directions in the treatment and prevention of bone metastases.
Coleman RE
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S32-8. PubMed ID: 12562049
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
7. The role of bisphosphonates in breast cancer.
Coleman RE
Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of bisphosphonates: promising preclinical evidence.
Guise TA
Cancer Treat Rev; 2008; 34 Suppl 1():S19-24. PubMed ID: 18486348
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of zoledronic acid.
Green JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):3-11. PubMed ID: 12584689
[TBL] [Abstract][Full Text] [Related]
11. The role of bisphosphonates in early breast cancer.
Paterson AH
Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates for treatment and prevention of bone metastases.
Michaelson MD; Smith MR
J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
[TBL] [Abstract][Full Text] [Related]
13. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
14. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
15. The antitumor potential of bisphosphonates.
Clézardin P
Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
[TBL] [Abstract][Full Text] [Related]
16. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.
Lipton A
J Support Oncol; 2004; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects and anticancer applications of bisphosphonates.
Morgan G; Lipton A
Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in breast cancer: antitumor effects.
Aft R
Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
[TBL] [Abstract][Full Text] [Related]
20. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
